Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name ALT-803
Trade Name
Synonyms N-803|N803|N 803|nogapendekin alfa|ALT803|ALT 803
Drug Descriptions

ALT-803 (nogapendekin alfa) is a fusion protein comprising a mutant version of IL-15 with increased activity and IL-15Ra fused to the Fc region of IgG1, which activates CD8+ T-cells and promotes effector activity, potentially resulting in increased antitumor immune response (PMID: 24404427, PMID: 31338557).

DrugClasses
CAS Registry Number 1850381-92-8
NCIT ID C107503

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Aldoxorubicin + ALT-803 + Avelumab + Bevacizumab + Capecitabine + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + Gemcitabine + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Oxaliplatin ALT-803 Aldoxorubicin Avelumab Bevacizumab Capecitabine Cyclophosphamide ETBX-011 ETBX-021 ETBX-051 ETBX-061 Fluorouracil GI-4000 GI-6207 GI-6301 Gemcitabine Leucovorin Nab-paclitaxel Oxaliplatin haNK cells 0 2
Aldoxorubicin + ALT-803 + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Oxaliplatin + Regorafenib + Trastuzumab ALT-803 Aldoxorubicin Avelumab Capecitabine Cetuximab Cyclophosphamide ETBX-011 ETBX-021 ETBX-051 ETBX-061 Fluorouracil GI-4000 GI-6207 GI-6301 Leucovorin Nab-paclitaxel Oxaliplatin Regorafenib Trastuzumab haNK cells 0 1
Aldoxorubicin + ALT-803 + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Sorafenib ALT-803 Aldoxorubicin Avelumab Capecitabine Cetuximab Cyclophosphamide ETBX-011 ETBX-051 ETBX-061 Fluorouracil GI-4000 GI-6207 GI-6301 Leucovorin Nab-paclitaxel Sorafenib haNK cells 0 1
Aldoxorubicin + ALT-803 + Avelumab + Cetuximab + ETBX-051 + ETBX-061 + GI-6301 + haNK cells ALT-803 Aldoxorubicin Avelumab Cetuximab ETBX-051 ETBX-061 GI-6301 haNK cells 0 1
Aldoxorubicin + ALT-803 + Avelumab + Cisplatin + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6301 + haNK cells + Paclitaxel ALT-803 Aldoxorubicin Avelumab Cisplatin Cyclophosphamide ETBX-011 ETBX-051 ETBX-061 Fluorouracil GI-4000 GI-6301 Paclitaxel haNK cells 0 1
Aldoxorubicin + ALT-803 + Avelumab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel ALT-803 Aldoxorubicin Avelumab Cyclophosphamide ETBX-011 ETBX-051 ETBX-061 Fluorouracil GI-4000 GI-6207 GI-6301 Leucovorin Nab-paclitaxel haNK cells 0 1
Aldoxorubicin + ALT-803 + Cyclophosphamide + Gemcitabine + Nab-paclitaxel ALT-803 Aldoxorubicin Cyclophosphamide Gemcitabine Nab-paclitaxel 0 1
Aldoxorubicin + ALT-803 + Cyclophosphamide + Gemcitabine + Nab-paclitaxel + PD-L1.t-haNK cells ALT-803 Aldoxorubicin Cyclophosphamide Gemcitabine Nab-paclitaxel PD-L1.t-haNK cells 0 1
ALT-803 ALT-803 0 12
ALT-803 + Atezolizumab + Ramucirumab ALT-803 Atezolizumab Ramucirumab 0 1
ALT-803 + Avelumab + Bevacizumab + ETBX-011 + GI-4000 ALT-803 Avelumab Bevacizumab ETBX-011 GI-4000 0 1
ALT-803 + Avelumab + haNK cells ALT-803 Avelumab haNK cells 0 1
ALT-803 + BCG solution ALT-803 BCG solution 0 1
ALT-803 + Bintrafusp alfa ALT-803 Bintrafusp alfa 0 2
ALT-803 + Bintrafusp alfa + CV301 ALT-803 Bintrafusp alfa CV301 0 1
ALT-803 + Bintrafusp alfa + CV301 + NHS-IL12 ALT-803 Bintrafusp alfa CV301 NHS-IL12 0 1
ALT-803 + Bintrafusp alfa + Epacadostat + FPV-Brachyury + MVA-BN-Brachyury ALT-803 Bintrafusp alfa Epacadostat FPV-Brachyury MVA-BN-Brachyury 0 1
ALT-803 + Bintrafusp alfa + ETBX-011 + ETBX-051 + ETBX-061 ALT-803 Bintrafusp alfa ETBX-011 ETBX-051 ETBX-061 0 1
ALT-803 + Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury ALT-803 Bintrafusp alfa FPV-Brachyury MVA-BN-Brachyury 0 1
ALT-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab ALT-803 Carboplatin Nab-paclitaxel Pembrolizumab 0 1
ALT-803 + Carboplatin + Pembrolizumab + Pemetrexed Disodium ALT-803 Carboplatin Pembrolizumab Pemetrexed Disodium 0 1
ALT-803 + CD19 t-haNK cells + Rituximab ALT-803 CD19 t-haNK cells Rituximab 0 0
ALT-803 + Cetuximab + haNK cells ALT-803 Cetuximab haNK cells 0 0
ALT-803 + Cetuximab + PD-L1.t-haNK cells ALT-803 Cetuximab PD-L1.t-haNK cells 0 1
ALT-803 + CIML-NK cells ALT-803 CIML-NK cells 0 2
ALT-803 + CIML-NK cells + Ipilimumab ALT-803 CIML-NK cells Ipilimumab 0 1
ALT-803 + Cisplatin + Pembrolizumab + Pemetrexed Disodium ALT-803 Cisplatin Pembrolizumab Pemetrexed Disodium 0 1
ALT-803 + Cyclophosphamide + Fludarabine ALT-803 Cyclophosphamide Fludarabine 0 2
ALT-803 + Cyclophosphamide + PD-L1.t-haNK cells + Sacituzumab govitecan-hziy ALT-803 Cyclophosphamide PD-L1.t-haNK cells Sacituzumab govitecan-hziy 0 1
ALT-803 + Elotuzumab + Melphalan ALT-803 Elotuzumab Melphalan 0 1
ALT-803 + ETBX-011 ALT-803 ETBX-011 0 1
ALT-803 + ETBX-011 + ETBX-051 + ETBX-061 + Retifanlimab ALT-803 ETBX-011 ETBX-051 ETBX-061 Retifanlimab 0 1
ALT-803 + ETBX-011 + ETBX-051 + ETBX-061 + Retifanlimab + SX-682 ALT-803 ETBX-011 ETBX-051 ETBX-061 Retifanlimab SX-682 0 1
ALT-803 + Gemcitabine + Nab-paclitaxel ALT-803 Gemcitabine Nab-paclitaxel 0 1
ALT-803 + H1299 cell lysate vaccine + Montanide ISA 51 ALT-803 H1299 cell lysate vaccine Montanide ISA 51 0 1
ALT-803 + HER2 Vaccine + Lenvatinib + Pembrolizumab ALT-803 HER2 Vaccine Lenvatinib Pembrolizumab 0 1
ALT-803 + Ipilimumab ALT-803 Ipilimumab 0 0
ALT-803 + m-ceNK cells ALT-803 m-ceNK cells 0 1
ALT-803 + Nivolumab ALT-803 Nivolumab 0 2
ALT-803 + PD-L1.t-haNK cells + Pembrolizumab ALT-803 PD-L1.t-haNK cells Pembrolizumab 0 2
ALT-803 + Pembrolizumab ALT-803 Pembrolizumab 0 4
ALT-803 + Rituximab ALT-803 Rituximab 0 1


Additional content available in CKB BOOST